|
Jul 24
|
ASX Growth Stocks With High Insider Stakes
|
|
Jul 24
|
High Growth Tech Stocks To Watch In Australia July 2025
|
|
Jul 22
|
Mesoblast Limited (MESO) Is Up 40.59% in One Week: What You Should Know
|
|
Jul 21
|
[Latest] Global Cardiac Tissue Engineering Market Size/Share Worth USD 2,943.92 Million by 2034 at a 16.65% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
|
|
Jul 18
|
Successful Commercial Launch of Ryoncil®
|
|
Jul 1
|
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
|
|
Jun 29
|
Mesoblast (MESO) Gets 7 Years of Orphan-drug Exclusive Approval from US FDA for Ryoncil
|
|
Jun 12
|
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
|
|
Apr 17
|
Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
|
|
Mar 13
|
Ryoncil® Product Information Now Available in All Four Major Drug Pricing Compendia in United States
|
|
Mar 12
|
Mesoblast CEO to Deliver Featured Presentation at ISCT North America Virtual Town Hall
|
|
Mar 10
|
Mesoblast Limited (MESO): Among the Best Australian Stocks to Buy According to Billionaires
|
|
Feb 26
|
Mesoblast Sets Ryoncil® Price Based on Economic Value of Treatment With Planned Product Availability This Quarter
|
|
Feb 26
|
Mesoblast Limited (MESO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
|
|
Feb 23
|
Dr. Gregory George MD PhD Joins Mesoblast Board
|
|
Feb 19
|
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
|
|
Jan 3
|
MESO Stock Surges 80% in a Month After FDA Approval of GVHD Drug
|
|
Jan 3
|
Exploring 3 High Growth Tech Stocks In Australia
|
|
Oct 19
|
Mesoblast Advances Cellular Medicines Amid FDA Hopes
|
|
Oct 10
|
ASX Growth Companies With High Insider Ownership In October 2024
|